Close Menu

Advances in Clinical Genomics Profiling

BostonGene will analyze the tumors of patients enrolled in NEC or NEC-affiliated clinical trials and NEC will use the data to help improve treatment responses.  

The initiative will offer a liquid biopsy tool that only requires a blood draw for cancer treatment selection instead of a tissue biopsy. 

A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.

Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.

The findings underscore the utility of universal germline testing in young adults diagnosed with cancers that are more common in older populations.